Trial Profile
Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Ciclosporin; Methotrexate
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 04 Dec 2019 According to a Bristol-Myers Squibb media release, based on the findings from this study, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA (abatacept) for the prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors.
- 18 Nov 2009 New trial record